Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Lilly

FDA Approves New Alzheimer's Drug To Slow Disease Progression

FDA approves Eli Lilly's donanemab for early Alzheimer's, offering hope for patients and caregivers. Treatment priced at 5 per vial.

Top News

FDA approves second Alzheimer’s drug that can slow onset of disease

Eli Lilly says Kisunla demonstrated ‘meaningful results’ for people showing early symptoms of the disease

The Guardian - US

FDA approves a second Alzheimer's drug that can modestly slow disease

U.S. health officials have approved a new Alzheimer’s drug that can modestly slow the disease

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Mega-Cap Stocks to Consider Before They're Worth $1 Trillion

Mega-cap stocks are the flavor of the season, and these three big names are the next set of contenders racing towards the $1 trillion market cap club.

Barchart

Weight loss drug could ease sleep apnoea in people with obesity, study says

Research raises possibility that tirzepatide could become first pharmaceutical treatment for the sleeping disorder

The Guardian - UK

WHO and Eli Lilly caution patients against falling for fake versions of popular weight-loss drugs

The World Health Organization and drugmaker Eli Lilly and Co. are warning patients to be wary of fake versions of weight-loss and diabetes medicines

The Independent UK

Alzheimer's drug that can slow disease gets backing from FDA advisers

Federal health advisers have endorsed a closely watched Alzheimer’s drug from Eli Lilly for people with mild dementia

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Should a CFO switch industries? For these Fortune 500 finance chiefs, a new sector provided a career boost

Most CFOs have more options than they think, according to an expert.

Fortune

Alphabet’s next CFO Anat Ashkenazi ‘fills a void’ for the company at key time during AI Revolution, says top analyst

Ashkenazi is a 23-year veteran of Eli Lilly and Company.

Fortune

Google and Alphabet’s new CFO is Eli Lilly’s Anat Ashkenazi

Ashkenazi will have the task of investing in the company’s next wave of growth in the AI era.

Fortune

1 'Strong Buy' Dividend Stock to Buy and Hold

Discover why Eli Lilly is considered a 'strong buy' as it capitalizes on the growing demand for diabetes and obesity treatments, backed by its robust financial performance and promising future prospects.

Barchart

Eli Lilly (LLY) or Pfizer (PFE): Which Stock Can Surge From Earnings?

Amid increasing healthcare spending, breakthroughs in genomics and personalized medicine, and the adoption of new technologies, the pharma industry is booming. So, let’s analyze Eli Lilly (LLY) and Pfizer (PFE) to determine which pharma stock will surge from their first-quarter earnings. Read on to find out.

StockNews.com

Highly Awaited Alzheimer's Drug Hit By Delays

Eli Lilly's highly anticipated Alzheimer's drug has been held back for further review by regulators, the US pharmaceutical giant said Friday, in a blow for patients with the devastating brain disorder.

International Business Times

‘It feels like we’ve been lobotomised’: the possible sexual consequences of SSRIs

Long-term sexual dysfunction is a side-effect for some patients who take these widely prescribed antidepressants, and can leave sufferers devastated

The Guardian - UK

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Biotech Stocks Climbing the Ranks to Watch

The biotech industry is thriving on growing applications across sectors from healthcare to agriculture, favorable government funding and policies, and technological breakthroughs. Amid this backdrop, quality biotech stocks UroGen Pharma (URGN), Foghorn Therapeutics (FHTX), and Galapagos (GLPG) might be ideal additions to one’s watchlist. Read on….

Barchart

2 Obesity Treatment Stocks Morgan Stanley Likes More than Novo Nordisk

While Novo Nordisk's Wegovy currently dominates the obesity treatment market, Morgan Stanley sees more upside potential for LLY and AZN stocks going forward.

Barchart

It's Not Too Late to Buy Eli Lilly Stock. Here's Why.

J.P. Morgan thinks sales of weight-loss drugs could exceed $100 billion by 2030. That's good news for Eli Lilly, which is now the largest pharma company by market capitalization and the 9th-biggest S&P 500 stock. Here's why LLY stock looks poised to put on even more weight in the months…

The Guardian - UK

Weight loss injection to be made available in UK within weeks

Mounjaro will come in a four-dose device known as a KwikPen for people with type 2 diabetes or obesity

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

$100 million gift from Lilly Endowment aims to shore up HBCU endowments

The United Negro College Fund announced a donation of $100 million from the Lilly Endowment, the single largest unrestricted gift to the organization since its founding 80 years ago

Barchart

Iron Condor Alert: LLY Stock Could Net 40% In 4 Weeks

Eli Lilly (LLY) is showing elevated implied volatility with an IV Percentile of 98%, and that could mean it’s a good time for an iron condor trade.

The Independent UK

Eli Lilly starts website to connect patients with new obesity treatment, Zepbound, other drugs

Eli Lilly has launched a unique website to connect U.S. patients seeking obesity treatment to doctors, dieticians and its new weight-loss drug, Zepbound

Top News

Eli Lilly Launches Unique Website Connecting Patients to Obesity Care+

Eli Lilly launches LillyDirect, a one-of-a-kind website connecting patients seeking obesity treatment to doctors and its weight-loss drug. Streamlining hea...

Fortune

Eli Lilly cracks down on the use of weight loss drugs Mounjaro and Zepbound for ‘cosmetic’ reasons instead of diabetes and obesity

The news comes as rampant demand for the reputed “miracle drugs” leads to nationwide shortages.

Barchart

Eli Lilly Stock: Buy or Sell?

Eli Lilly's diversified portfolio and high demand for its weight-loss drugs have pushed it to the top of Wall Street's list of top pharma stocks for 2024. Is now the time to buy?

Kiplinger

Insulin Now Available for $35 a Month for Many Americans

Insulin price caps from Eli Lilly, Novo Nordisk and Sanofi take effect this month.

1 … 8 9 10 11

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the World Health Organization

552 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.